{{Rsnum
|rsid=3799488
|Gene=IFNGR1
|Chromosome=6
|position=137198643
|Orientation=plus
|GMAF=0.1382
|Gene_s=IFNGR1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 2.7 | 24.8 | 72.6
| HCB | 2.9 | 38.2 | 58.8
| JPT | 8.8 | 45.1 | 46.0
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 7.0 | 93.0
| CHB | 2.9 | 38.2 | 58.8
| CHD | 11.2 | 27.1 | 61.7
| GIH | 2.0 | 17.8 | 80.2
| LWK | 0.0 | 1.8 | 98.2
| MEX | 5.3 | 26.3 | 68.4
| MKK | 0.0 | 1.3 | 98.7
| TSI | 0.0 | 21.6 | 78.4
| HapMapRevision=28
}}{{PMID Auto
|PMID=21859832
|Title=Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival
|OA=1
}}

{{PMID Auto
|PMID=16449530
|Title=Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma.
|OA=1
}}

{{PMID Auto
|PMID=17327408
|Title=Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.
|OA=1
}}

{{PMID Auto
|PMID=18633131
|Title=Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.
|OA=1
}}

{{PMID Auto
|PMID=19066394
|Title=Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma.
|OA=1
}}

{{PMID Auto
|PMID=19356949
|Title=Cytokine SNPs: Comparison of allele frequencies by race and implications for future studies.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}